Lokivetmab
subcutaneous injection | |
|---|---|
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] It acts against interleukin 31 (IL-31),[2] which is a cytokine involved in causing itchiness (pruritus).[2] Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.[3]
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016,[3] and it was approved by the European Medicines Agency in 2017.[4] Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.[4]
References
- ^ "Zoetis earns license for Cytopoint skin therapy". Veterinary Practice News. 4 January 2017. Retrieved 2018-07-06.
- ^ PMID 29056696.
- ^ a b McKay L (13 July 2017). "Making a difference for dogs with atopic dermatitis: When to use Apoquel and when to use Cytopoint". dvm360.com. Retrieved 2018-07-07.
- ^ S2CID 20166012.
External links
- "Lokivetmab". Drug Information Portal. U.S. National Library of Medicine.